Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.

Cheng-Wei ChanChu-Leng YuJiunn-Cherng LinYu Cheng HsiehChe-Chen LinChen-Ying HungCheng-Hung LiYing-Chieh LiaoChu-Pin LoJin-Long HuangChing-Heng LinTsu-Juey Wu

Published in: Cardiovascular diabetology (2018)

Both TZD and AGI, when used as an add-on drug to metformin were associated with lower MACE risk when compared with SU added to metformin in this retrospective cohort study. Trial registration CE13152B-3. Registered 7 Mar, 2013, retrospectively registered.

Keyphrases

type diabetes
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
clinical trial
prognostic factors
study protocol
molecular docking
glycemic control
patient reported outcomes
cross sectional
metabolic syndrome
phase ii
adipose tissue
skeletal muscle
open label
weight loss